Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TECH Stock Forecast 2025-2026
$48.24
Current Price
$7.50B
Market Cap
Buy 10
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to TECH Price Targets
+86.6%
To High Target of $90.00
+45.1%
To Median Target of $70.00
+5.7%
To Low Target of $51.00
TECH Price Momentum
-3.4%
1 Week Change
-3.5%
1 Month Change
-41.8%
1 Year Change
-33.0%
Year-to-Date Change
-43.6%
From 52W High of $85.57
+4.8%
From 52W Low of $46.01
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Bio-Techne (TECH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TECH and similar high-potential opportunities.
Latest TECH Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, TECH has a bullish consensus with a median price target of $70.00 (ranging from $51.00 to $90.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $48.24, the median forecast implies a 45.1% upside. This outlook is supported by 10 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from John Vinh at Keybanc, projecting a 86.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECH Analyst Ratings
10
Buy
5
Hold
0
Sell
TECH Price Target Range
Low
$51.00
Average
$70.00
High
$90.00
Current: $48.24
Latest TECH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | UBS | Dan Leonard | Buy | Maintains | $70.00 |
| May 8, 2025 | Stifel | Daniel Arias | Hold | Maintains | $60.00 |
| May 8, 2025 | Benchmark | Robert Wasserman | Buy | Maintains | $75.00 |
| May 8, 2025 | RBC Capital | Conor McNamara | Sector Perform | Maintains | $63.00 |
| Apr 9, 2025 | Keybanc | Paul Knight | Sector Weight | Downgrade | $0.00 |
| Apr 8, 2025 | Keybanc | Sector Weight | Downgrade | $0.00 | |
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Initiates | $75.00 |
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $70.00 |
| Feb 19, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $68.00 |
| Feb 6, 2025 | RBC Capital | Conor McNamara | Sector Perform | Maintains | $80.00 |
| Feb 6, 2025 | Keybanc | John Vinh | Overweight | Maintains | $90.00 |
| Feb 6, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $90.00 |
| Oct 31, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $88.00 |
| Oct 31, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $84.00 |
| Aug 13, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $95.00 |
| Aug 8, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $82.00 |
| Aug 8, 2024 | RBC Capital | Conor McNamara | Sector Perform | Maintains | $70.00 |
| May 22, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $85.00 |
| May 2, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $95.00 |
| May 2, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $81.00 |
Bio-Techne Corporation (TECH) Competitors
The following stocks are similar to Bio-Techne based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Techne Corporation (TECH) Financial Data
Bio-Techne Corporation has a market capitalization of $7.50B with a P/E ratio of 57.7x. The company generates $1.21B in trailing twelve-month revenue with a 10.9% profit margin.
Revenue growth is +4.2% quarter-over-quarter, while maintaining an operating margin of +14.1% and return on equity of +6.5%.
Valuation Metrics
Market Cap
$7.50B
Enterprise Value
$8.37B
P/E Ratio
57.7x
PEG Ratio
21.9x
Price/Sales
6.2x
Growth & Margins
Revenue Growth (YoY)
+4.2%
Gross Margin
+67.9%
Operating Margin
+14.1%
Net Margin
+10.9%
EPS Growth
-54.0%
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
3.7x
Debt/Equity
21.0x
ROE
+6.5%
ROA
+5.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Bio-Techne Corporation (TECH) Business Model
About Bio-Techne Corporation
What They Do
Develops and manufactures biological products for research.
Business Model
The company generates revenue by providing a wide range of high-quality biotechnological products and solutions for the research and clinical diagnostics markets. Its offerings include proteins, antibodies, assay kits, and laboratory services, catering to sectors like biotechnology, pharmaceuticals, and academic research.
Additional Information
Bio-Techne is committed to innovation and quality, playing a crucial role in advancing modern biology and medicine. The company is involved in significant research areas, including cancer research and immunology, and maintains a strong global presence, impacting the life sciences landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3,100
CEO
Mr. Kim Kelderman
Country
United States
IPO Year
1992
Website
www.bio-techne.comBio-Techne Corporation (TECH) Latest News & Analysis
Latest News
Quick Summary
Bio-Techne Corporation (NASDAQ: TECH) will present its new spatial biology and cell and gene therapy solutions at the ASGCT 2025 meeting in New Orleans from May 13-17.
Why It Matters
Bio-Techne's showcase at a major industry conference highlights its innovation in spatial biology and therapy solutions, potentially boosting investor confidence and market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Kytopen and Bio-Techne have partnered to enhance cell therapy manufacturing using TcBuster™ for efficient gene integration and Flowfect® for rapid cell processing.
Why It Matters
The partnership enhances cell therapy manufacturing efficiency, potentially increasing market competitiveness and profitability for both companies, impacting their stock values positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bio-Techne Corporation (NASDAQ: TECH) CEO Kim Kelderman will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 10:40 a.m. PDT. A live webcast will be available on their IR website.
Why It Matters
Bio-Techne's CEO presentation at a major healthcare conference could signal strategic insights and potential developments, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bio-Techne exceeded Q3 profit estimates, fueled by growth in its research products segment, and announced a new share buyback program.
Why It Matters
Bio-Techne's profit beat signals strong performance and growth potential, while a new share buyback program may enhance shareholder value and confidence in the company's future prospects.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Maryland Congresswoman April McClain Delaney made a notable stock bet on a low-profile biotech company, according to Finbold's congressional trading radar.
Why It Matters
Suspicious trading by a congresswoman could indicate insider knowledge, potentially impacting stock performance and investor sentiment in the biotech sector.
Source: Finbold
Market Sentiment:
Negative
Quick Summary
Bio-Techne Corporation (NASDAQ: TECH) will host its Q3 2025 Earnings Conference Call on May 7, 2025, at 9:00 AM ET, with key executives participating and a Q&A session to follow.
Why It Matters
The earnings call provides insights into Bio-Techne's financial performance, strategic direction, and market outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TECH Stock
What is Bio-Techne Corporation's (TECH) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Bio-Techne Corporation (TECH) has a median price target of $70.00. The highest price target is $90.00 and the lowest is $51.00.
Is TECH stock a good investment in 2025?
According to current analyst ratings, TECH has 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $48.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECH stock?
Wall Street analysts predict TECH stock could reach $70.00 in the next 12 months. This represents a 45.1% increase from the current price of $48.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bio-Techne Corporation's business model?
The company generates revenue by providing a wide range of high-quality biotechnological products and solutions for the research and clinical diagnostics markets. Its offerings include proteins, antibodies, assay kits, and laboratory services, catering to sectors like biotechnology, pharmaceuticals, and academic research.
What is the highest forecasted price for TECH Bio-Techne Corporation?
The highest price target for TECH is $90.00 from John Vinh at Keybanc, which represents a 86.6% increase from the current price of $48.24.
What is the lowest forecasted price for TECH Bio-Techne Corporation?
The lowest price target for TECH is $51.00 from at , which represents a 5.7% increase from the current price of $48.24.
What is the overall TECH consensus from analysts for Bio-Techne Corporation?
The overall analyst consensus for TECH is bullish. Out of 18 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $70.00.
How accurate are TECH stock price projections?
Stock price projections, including those for Bio-Techne Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 7:35 AM UTC